We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).
- Authors
Gauler, T C; Besse, B; Mauguen, A; Meric, J B; Gounant, V; Fischer, B; Overbeck, T R; Krissel, H; Laurent, D; Tiainen, M; Commo, F; Soria, J C; Eberhardt, W E E
- Abstract
The objective of this multicenter, prospective uncontrolled phase II trial was to determine efficacy, safety and tolerability of vatalanib, an oral angiogenesis inhibitor targeting all known vascular endothelial growth factor receptors, in the second-line treatment of non-small-cell lung cancer (NSCLC).
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Vol 23, Issue 3, p678
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mdr255